Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO7310729
XmAb24306 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose escalation | EXPERIMENTAL | Participants will receive escalating doses of XmAb24306 with daratumumab up to the maximum tolerated dose (MTD) |
| Dose expansion | EXPERIMENTAL | Participants will receive XmAb24306 with daratumumab at the recommended phase 2 dose (RP2D) |
| Phase 1a Dose Escalation | EXPERIMENTAL | Participants will receive XmAb24306 until study treatment discontinuation or study termination. |
| Phase 1a Dose Expansion | EXPERIMENTAL | Participants will receive XmAb24306 until study treatment discontinuation or study termination. |
| Phase 1b Dose Escalation | EXPERIMENTAL | Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination. |
| Phase 1b Dose Expansion | EXPERIMENTAL | Participants will receive XmAb24306 and atezolizumab until study treatment discontinuation or study termination. |
| Name | Type | Description |
|---|---|---|
| XmAb24306 | DRUG | XmAb24306 will be given via intravenous (IV) infusion |
| Daratumumab | DRUG | Participants will receive daratumumab via subcutaneous (SC) injection every week for Cycles 1-4, every 2 weeks for Cycles 5-12, and every 4 weeks thereafter (cycle length = 2 weeks for Cycles 1-12 and 4 weeks thereafter) |
| Atezolizumab | DRUG | Participants will receive IV XmAb24306 followed by IV atezolizumab |
Inclusion Criteria: * Life expectancy of at least 12 weeks * Measurable disease, as defined by the protocol * Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody * Best response of stable disease or better ...
Top 20 of 25 competitors
XmAb24306 is an investigational oncology drug being studied for the treatment of solid tumors and multiple myeloma. It is currently in Phase 1 clinical development. The drug is being evaluated as a single agent and in combination with other therapies for these cancer indications.
XmAb24306 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is currently in Phase 1 clinical trials for oncology indications, including solid tumors and multiple myeloma.
XmAb24306 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are being conducted to evaluate its safety and pharmacokinetics in patients with solid tumors and multiple myeloma.
XmAb24306 has been studied in two completed Phase 1 clinical trials. NCT04250155 evaluated the drug as a single agent and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. NCT05243342 evaluated the drug in combination with daratumumab in patients with relapsed or refractory multiple myeloma.